Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 3/20 | 0.50 |
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 7/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095194 | 0.90 | PTPN11 (0.41) | PTPN11PTGESPPARGCYP3A4CYP3A5 | |
| SCHEMBL4094952 | 0.90 | PTPN11 (0.51) | PTPN11PTGESPPARGCYP3A4CYP3A5 | |
| SCHEMBL4096505 | 0.84 | PTGES (0.44) | PTPN11PTGESPPARGPPARABCL2 | |
| SCHEMBL3572273 | 0.81 | PTGES (0.45) | PTGESPPARGPPARA | |
| SCHEMBL4100038 | 0.80 | PTGES (0.60) | PTPN11PTGESCYP3A4CYP3A5PTPN5 | |
| SCHEMBL4228390 | 0.77 | PPARG (0.50) | PTGESPPARGPPARA | |
| SCHEMBL4916822 | 0.76 | PPARG (0.47) | PPARGPPARASCN9A | |
| SCHEMBL4104398 | 0.76 | PPARG (0.41) | PTPN11PTGESPPARGPPARAPPARD | |
| SCHEMBL4227238 | 0.76 | PTGES (0.41) | PTGESPPARGPPARAPTPN5 | |
| SCHEMBL4913507 | 0.76 | PPARG (0.45) | PTGESPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | PTPN11 1154/4885PTGES 47/4885PPARG 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.